Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus.
OBJECTIVE
Inhibition of T cell DNA methylation causes autoreactivity in vitro and a lupus-like disease in vivo, suggesting that T cell DNA hypomethylation may contribute to autoimmunity. The hypomethylation effects are due, in part, to overexpression of lymphocyte function-associated antigen 1 (LFA-1) (CD11a/CD18). Importantly, T cells from patients with active lupus have hypomethylated DNA and overexpress LFA-1 on an autoreactive subset, suggesting that the same mechanism could contribute to human lupus. The present study investigated the nature of the methylation change that affects LFA-1 expression in vitro and in human lupus.


METHODS
Bisulfite sequencing was used to determine the methylation status of the ITGAL promoter and flanking regions in T cells from lupus patients and healthy subjects, and in T cells treated with DNA methylation inhibitors. "Patch" methylation of promoter sequences in reporter constructs was used to determine the functional significance of the methylation changes.


RESULTS
Hypomethylation of specific sequences flanking the ITGAL promoter was seen in T cells from patients with active lupus and in T cells treated with 5-azacytidine and procainamide. Patch methylation of this region suppressed ITGAL promoter function.


CONCLUSIONS
DNA methylation changes occur in specific sequences that regulate LFA-1 expression in lupus T cells and in the hypomethylation model, indicating that altered methylation of specific genes may play a role in the pathogenesis of lupus.
Cancer Center and Geriatric Center, University of Michigan, Ann Arbor, MI 48109, USA.
Qianjin
Q
Lu
Mariana
M
Kaplan
Donna
D
Ray
Doreen
D
Ray
Sima
S
Zacharek
David
D
Gutsch
Bruce
B
Richardson
D000328:Adult; D015551:Autoimmunity / Q000235:genetics; D001374:Azacitidine / Q000494:pharmacology; D002478:Cells, Cultured; D019175:DNA Methylation / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D015870:Gene Expression / Q000276:immunology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000235:genetics* / Q000378:metabolism*; D016169:Lymphocyte Function-Associated Antigen-1 / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011342:Procainamide / Q000494:pharmacology; D011401:Promoter Regions, Genetic / Q000276:immunology; D013601:T-Lymphocytes / Q000166:cytology / Q000378:metabolism
D004791:Enzyme Inhibitors; D016169:Lymphocyte Function-Associated Antigen-1; D010975:Platelet Aggregation Inhibitors; D011342:Procainamide; D001374:Azacitidine